DBV Technologies to Participate in Upcoming Investor Conferences

Rhea-AI Summary

DBV Technologies announced its participation in several upcoming virtual investor conferences. CEO Daniel Tassé will host fireside chats at the following:

• Credit Suisse Healthcare Conference: November 11, 2020, at 12:30 PM ET
• Stifel Healthcare Conference: November 16, 2020, at 8:00 AM ET
• Evercore HealthconX: December 1, 2020, at 12:35 PM ET

Webcasts will be available on the company’s website, with replays posted afterward. DBV focuses on developing Viaskin™, an innovative immunotherapy platform for food allergies.

Montrouge, France, November 9, 2020
DBV Technologies to Participate in Upcoming Investor Conferences

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the following virtual investor conferences. At each conference, Daniel Tassé, Chief Executive Officer, will participate in a fireside chat.

Credit Suisse Healthcare Conference, November 9-12.
The fireside chat will take place on Wednesday, November 11, 2020 at 12:30PM ET.

Stifel Healthcare Conference, November 16.
The fireside chat will take place on Monday, November 16, 2020 at 8AM ET.  

Evercore HealthconX, December 1-3.
The fireside chat will take place on Tuesday, December 1, 2020 at 12:35PM ET.  

A live webcast of the fireside chats will be available on the Investors & Media section of the Company’s website:
https://www.dbv-technologies.com/investor-relations/

A replay of the presentations will also be available on DBV’s website after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin™ is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin™ Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Relations Contact
Anne Pollak
+ 1 (857) 529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
+ 1 (646) 842-2393
angela.marcucci@dbv-technologies.com

Attachment

• PDF Version

FAQ

What is DBV Technologies planning for the investor conferences in November 2020?

DBV Technologies will participate in multiple virtual investor conferences, featuring CEO Daniel Tassé in fireside chats.

When will DBV Technologies' fireside chat at the Credit Suisse Healthcare Conference take place?

The fireside chat at the Credit Suisse Healthcare Conference is scheduled for November 11, 2020, at 12:30 PM ET.

What is the date and time for DBV Technologies' participation in the Stifel Healthcare Conference?

DBV Technologies' fireside chat at the Stifel Healthcare Conference will occur on November 16, 2020, at 8:00 AM ET.

When can investors listen to DBV Technologies at the Evercore HealthconX event?

DBV Technologies will participate in the Evercore HealthconX event on December 1, 2020, at 12:35 PM ET.

Where can I find the webcasts for DBV Technologies' investor conference presentations?

The webcasts for DBV Technologies' investor conference presentations will be available on the company's website.